Treatments for Alzheimer’s, finally

As Americans prepare to vote in the November 3 midterm elections, the FT’s chief economics commentator Martin Wolf asks what the result will mean for Donald Trump, the future of US democracy and America's place in the world. In the third of a six-part series, Martin speaks to pol ...  Show more

Alphabet’s share price fell just over 12 percent on Thursday, and UK startup Nscale is banking on a troubled US data centre project to underpin its planned $35bn IPO. Plus, we look at what’s next for the ECB now that its president Christine Lagarde announced she’s stepping down.M ...  Show more

The former prime minister says it’s his “happiest day” as president of Alzheimer’s Research UK, after the discovery of the first drug to slow the disease.He also speaks about whether he did enough during his premiership to support those who needed dementia care.And, the BBC’s hea ...  Show more

Last year, researchers announced that the Alzheimer’s drug lecanemab lowered the amount of amyloid protein plaques associated with the disease in the brains of participants in a clinical trial, and slowed their cognitive decline.Now, researchers are looking to drug combinations, ...  Show more

Just before the pandemic, the government promised a 'dementia moonshot' to blast us towards a dementia cure. What happened to it?Today: former prime minister David Cameron and Sunday Times science editor Ben Spencer on Britain’s fastest growing disease, dementia.This podcast was ...  Show more